Pancreatic Cancer Research

ResearcherThe Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research InstituteActive in the last 2 years

Andrea N. Riner

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2088-5400; OpenAlex author ID A5044965437. Sources: OpenAlex.

Their work

Papers
19 (first author 5, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
31
Papers, trials and grants by year

2020: 1 paper · 2021: 2 papers · 2022: 7 papers · 2023: 6 papers · 2024: 2 papers · 2025: none · 2026: 1 paper

Papers 19

  1. Neoadjuvant Radiation is Causally Linked to Increased Operative Time and Perioperative Blood Transfusion in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.jss.2026.01.031↗
  2. Heterogeneity of weight loss and transcriptomic signatures in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/jcsm.13390↗
  3. Infiltration of CD3+ and CD8+ lymphocytes in association with inflammation and survival in pancreatic cancer. Co-author DOI 10.1371/journal.pone.0297325↗
  4. Impact of Biopsy Attempts, Race, and Access on Time to Initiation of Treatment for Pancreatic Cancer. First author DOI 10.1007/s11605-022-05531-6↗
  5. A protein-based machine learning approach to the identification of inflammatory subtypes in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2023.06.007↗
  6. Ethical Considerations of Biopsies in Early-Stage Pancreatic Cancer. First author DOI 10.1200/op.23.00044↗
  7. Transcriptomic analysis of pancreatic adenocarcinoma specimens obtained from Black and White patients. Co-author DOI 10.1371/journal.pone.0281182↗
  8. Changing Practice Patterns and Improving Survival for Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers15184464↗
  9. Translocation of Oral Microbiota into the Pancreatic Ductal Adenocarcinoma Tumor Microenvironment. Co-author DOI 10.3390/microorganisms11061466↗
  10. The interleukin-1 axis and the tumor immune microenvironment in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.neo.2022.100789↗
  11. Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-XL-Specific Degrader DT2216. Co-author DOI 10.1158/1535-7163.mct-21-0474↗
  12. The oral microbiome, pancreatic cancer and human diversity in the age of precision medicine. First author DOI 10.1186/s40168-022-01262-7↗
  13. Eligibility Criteria Perpetuate Disparities in Enrollment and Participation of Black Patients in Pancreatic Cancer Clinical Trials. Co-author DOI 10.1200/jco.21.02492↗
  14. From bench to bedside: Pursuing equity in precision medicine approaches to pancreatic cancer care. First author DOI 10.3389/fonc.2022.1086779↗
  15. Patient-Derived Pancreatic Cancer Cells Induce C2C12 Myotube Atrophy by Releasing Hsp70 and Hsp90. Co-author DOI 10.3390/cells11172756↗
  16. Single-cell profiling of microenvironment components by spatial localization in pancreatic ductal adenocarcinoma. Co-author DOI 10.7150/thno.73222↗
  17. Diversity and Inclusion in Pancreatic Cancer Clinical Trials. First author DOI 10.1053/j.gastro.2021.06.079↗
  18. The Florida Pancreas Collaborative Next-Generation Biobank: Infrastructure to Reduce Disparities and Improve Survival for a Diverse Cohort of Patients with Pan… Co-author DOI 10.3390/cancers13040809↗
  19. Disparities in Pancreatic Ductal Adenocarcinoma-The Significance of Hispanic Ethnicity, Subgroup Analysis, and Treatment Facility on Clinical Outcomes. Co-author DOI 10.1002/cam4.3042↗

Closest collaborators

The 25 strongest of 31 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kelly M. Herremans · 16 shared papers, 2020–2026 · strength 2.93
  2. Steven J. Hughes · 12 shared papers, 2022–2026 · strength 2.32
  3. Jose Gilberto Trevino · 12 shared papers, 2020–2026 · strength 2.15
  4. Patrick W. Underwood · 7 shared papers, 2020–2024 · strength 1.15
  5. Ibrahim Nassour · 5 shared papers, 2022–2026 · strength 1.02
  6. Song Han · 5 shared papers, 2022–2024 · strength 0.90
  7. Vignesh Vudatha · 5 shared papers, 2022–2024 · strength 0.86
  8. Gerik W. Tushoski-Alemán · 4 shared papers, 2022–2024 · strength 0.71
  9. Thomas J. George · 4 shared papers, 2020–2024 · strength 0.66
  10. Riley P. Bohan · 3 shared papers, 2022–2023 · strength 0.55
  11. Christopher E Forsmark · 2 shared papers, 2023 · strength 0.38
  12. Kelley Lobean McKinley · 2 shared papers, 2022–2023 · strength 0.37
  13. Michael H. Gerber · 2 shared papers, 2022–2023 · strength 0.30
  14. Jordan A. McKean · 1 shared paper, 2026 · strength 0.29
  15. Miles E. Cameron · 2 shared papers, 2020–2022 · strength 0.28
  16. Lauren B. Solberg · 1 shared paper, 2023 · strength 0.22
  17. Jose Trevino · 1 shared paper, 2023 · strength 0.19
  18. Robert A. Winn · 1 shared paper, 2021 · strength 0.19
  19. Sarah M. Judge · 1 shared paper, 2024 · strength 0.19
  20. Andrew R. Judge · 1 shared paper, 2024 · strength 0.19
  21. Hongyu Wu · 1 shared paper, 2022 · strength 0.17
  22. Yiping Li · 1 shared paper, 2022 · strength 0.17
  23. V. Ashutosh Rao · 1 shared paper, 2023 · strength 0.17
  24. Thomas G. Biel · 1 shared paper, 2023 · strength 0.17
  25. Tyler John Loftus · 1 shared paper, 2022 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.